Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension by Ulrich, S et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2008
Increased regulatory and decreased CD8+ cytotoxic T cells in the blood of
patients with idiopathic pulmonary arterial hypertension
Ulrich, S; Nicolls, M R; Taraseviciene, L; Speich, R; Voelkel, N
Abstract: BACKGROUND: An association between pulmonary arterial hypertension (PAH) and various
immune disorders is well established. Recently, the role of an intact immune system in protecting against
pulmonary angioproliferation was shown in an animal model. OBJECTIVE: To elucidate the role of T
cells in human PAH, we comparatively studied T cell subclasses with emphasis on regulatory T cells
(T(reg)) in the peripheral blood of patients with idiopathic pulmonary arterial hypertension (IPAH) and
healthy controls. METHODS: Isolated peripheral blood mononuclear cells from 36 patients diagnosed
with IPAH and 33 healthy controls were stained with fluorescently labeled monoclonal antibodies against
superficial T cell markers (CD3, CD4, CD8, CD25) and FoxP3, the intracellular marker of T(reg) cells.
The relative cell distribution was analyzed by flow cytometry. The functionality of patient and control
T(reg) cells was assessed by coculture of T(reg) with nonregulatory T cells from the same individual.
RESULTS: Significantly less CD8+ T cells (p = 0.02) and more CD25hi+ and FoxP3+CD4+ T cells
were found in the peripheral blood of patients compared with controls (p = 0.009 and p < 0.001, re-
spectively). The percentage of FoxP3+ cells within the CD25hi+CD4+ T(reg) cells was similar. T(reg)
cell functionality was equal in patients and controls. CONCLUSION: Our findings of decreased CD8+
T cells and increased T(reg) cells in the peripheral blood of patients with IPAH are novel and may have
implications for directing future research in the field to elucidate the differential role of T cells and the
immune system in IPAH. 2007 S. Karger AG, Basel
DOI: 10.1159/000111548
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: http://doi.org/10.5167/uzh-17098
Published Version
Originally published at:
Ulrich, S; Nicolls, M R; Taraseviciene, L; Speich, R; Voelkel, N (2008). Increased regulatory and de-
creased CD8+ cytotoxic T cells in the blood of patients with idiopathic pulmonary arterial hypertension.
Respiration, 75(3):272-280. DOI: 10.1159/000111548
Fax +41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
 Clinical Investigations 
 Respiration 2008;75:272–280 
 DOI: 10.1159/000111548 
 Increased Regulatory and Decreased CD8+ 
Cytotoxic T Cells in the Blood of Patients with 
Idiopathic Pulmonary Arterial Hypertension 
 Silvia Ulrich a, b    Mark R. Nicolls a    Laima Taraseviciene a    Rudolf Speich b    Norbert Voelkel a  
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cells was similar. T reg cell functionality was equal in patients 
and controls.  Conclusion: Our findings of decreased CD8+ T 
cells and increased T reg cells in the peripheral blood of pa-
tients with IPAH are novel and may have  implications for di-
recting future research in the field to elucidate the differential 
role of T cells and the immune system in IPAH. 
 Copyright © 2007 S. Karger AG, Basel 
 Introduction 
 Idiopathic pulmonary arterial hypertension (IPAH) is 
a progressive disease with a dismal prognosis ultimately 
leading to right ventricular failure and death. Lumen 
obliteration of the microscopically fine precapillary arte-
rioles due to endothelial proliferation and formation of 
complex vascular lesions are important aspects of the 
pathobiology  [1–3] . Although germline mutations of the 
gene encoding bone morphogenetic protein receptor II 
(BMPRII), a member of the transforming growth factor 
superfamily, have been identified in some patients with 
familial and sporadic IPAH  [4–7] , how germline BMPRII 
mutations promote the development of PAH remains un-
clear. Thus, other mechanisms contributing to the patho-
genesis of PAH are of great interest and currently under 
investigation. One controller of pulmonary hypertension 
may be the immune system, based on the following facts: 
 Key Words 
 CD4   CD8   CD25   FoxP3   Idiopathic pulmonary arterial 
hypertension   Regulatory T cells 
 Abstract 
 Background: An association between pulmonary arterial hy-
pertension (PAH) and various immune disorders is well estab-
lished. Recently, the role of an intact immune system in pro-
tecting against pulmonary angioproliferation was shown in 
an animal model.  Objective: To elucidate the role of T cells in 
human PAH, we comparatively studied T cell subclasses with 
emphasis on regulatory T cells (T reg ) in the peripheral blood 
of patients with idiopathic pulmonary arterial hypertension 
(IPAH) and healthy controls.  Methods:  Isolated peripheral 
blood mononuclear cells from 36 patients diagnosed with 
IPAH and 33 healthy controls were stained with fluorescently 
labeled monoclonal antibodies against superficial T cell 
markers (CD3, CD4, CD8, CD25) and FoxP3, the intracellular 
marker of T reg cells. The relative cell distribution was analyzed 
by flow cytometry. The functionality of patient and control 
T reg cells was assessed by coculture of T reg with nonregulatory 
T cells from the same individual.  Results: Significantly less 
CD8+ T cells (p = 0.02) and more CD25hi+ and FoxP3+CD4+ T 
cells were found in the peripheral blood of patients com-
pared with controls (p = 0.009 and p  ! 0.001, respectively). 
The percentage of FoxP3+ cells within the CD25hi+CD4+ T reg 
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PAH is associated with a number of collagen vascular 
 autoimmune disorders  [8–14] (where BMPRII mutations 
are not prevalent)  [15] ; secondly, patients with PAH often 
have antinuclear, antiphospholipid or other autoantibod-
ies  [16–20] ; plexiform lesions are surrounded by immune 
cells  [3, 21–23] , and alterations in blood cytokines have 
been reported  [24] . PAH also occurs in association with 
HIV infection, where CD4 lymphocytes and regulatory T 
cells are depleted  [25] . Recently, we showed that athymic 
rats, which lack T lymphocytes, develop severe angiopro-
liferative PAH when exposed to the vascular endothelial 
growth factor inhibitor SU5416 in a normoxic environ-
ment  [26–28] . If the immune system of these athymic rats 
was reconstituted by injecting splenocytes from  euthymic 
syngeneic animals before administration of SU5416, the 
animals were protected from the development of exuber-
ant pulmonary vascular lesions  [27] . Hence, an intact im-
mune system and especially the T cell compartment seem 
to play a role in the development of PAH. 
 How the immune system discriminates between self 
and non-self and establishes and maintains unresponsive-
ness to self has been a key issue in immunology since the 
proposition of the clonal selection theory  [29] . The contri-
bution of regulatory (or suppressor) T cells (T reg ) or even 
their existence as a cellular entity has been controversial 
until recently, mainly because of the lack of a reliable mark-
er to identify them and the ambiguity of their functions at 
the molecular level  [30] . Research in the last years has dis-
covered several cell surface markers that could operation-
ally differentiate T reg from other T cells  [31, 32] . Recently, 
FoxP3, a transcription factor of the forkhead/winged-helix 
family, has been identified as a very specific marker of T reg 
cells  [33–36] . FoxP3+ T reg cells have been shown to be es-
sential for the induction and maintenance of self-tolerance 
and prevention of T-cell-mediated autoimmunity  [36–38] . 
In healthy humans, this population accounts for 5–10% of 
the peripheral CD4+ T cells. Alterations in the number of 
T reg cells in the peripheral blood have been reported in 
various immune disorders, some of them associated with 
PAH, and cancer  [39–45] . Whereas T reg cells were found to 
be qualitatively and/or quantitatively deficient in many au-
toimmune diseases (e.g., multiple sclerosis, graft versus 
host disease, systemic lupus erythematosus, type I diabetes 
or rheumatoid arthritis)  [46–49] , they have been shown to 
be increased in some tumors and infections  [41, 42, 45, 46, 
50, 51] . The aim of the present study was to investigate pe-
ripheral blood T lymphocyte subsets with emphasis on T reg 
cells in IPAH compared with healthy controls in the hope 
of elucidating one step toward a better understanding of 
the role of the immune system in human PAH. 
 Material and Methods 
 Study Design and Subjects  
 The present study is a prospective clinical investigation on 
lymphocyte subsets in the peripheral blood of patients compared 
with healthy controls. Patients were diagnosed with IPAH ac-
cording to the WHO classification  [52] if the mean pulmonary 
artery pressure was  6 25 mm Hg along with a pulmonary arte-
rial occlusion pressure  ^  15 mm Hg assessed by right heart cath-
eterization, and if an extensive clinical work-up did not reveal 
other conditions responsible for pulmonary hypertension  [52] . 
Healthy volunteers working at the University of Colorado Health 
Sciences Center served as controls. The study was approved by the 
local institutional review board and subjects gave their written 
informed consent. 
 Blood Samples and Analysis of Lymphocyte Subsets 
 Venous blood samples were collected in heparin-treated tubes 
from each subject, and peripheral blood mononuclear cells 
(PBMCs) were separated immediately using Histopaque (Sigma-
Aldrich, St. Louis, Mo., USA) density gradient centrifugation. 
PBMCs were either processed within 24 h (18 patients and 23 con-
trols) or frozen at –20 ° C (18 patients and 10 controls) for up to 1 
month in PBMC freezing medium (Cambrex, Walkersville, Md., 
USA). 
 The FACS Calibur 4-color flow cytometer (BD Biosciences, 
N.Y., USA) was used to identify the cell type. Two million PBMCs 
each were stained with fluorescently labeled monoclonal antibod-
ies (mAbs) directed against superficial activation markers (anti-
CD3-PE, anti-CD8-FITC, anti-CD4-perCP, anti-CD25-APC) 
and against the intranuclear marker anti-FoxP3-PE. The superfi-
cial markers were all purchased from BD Bioscience, whereas the 
intracellular marker was purchased from eBioscience (San Diego, 
Calif., USA). In brief, for superficial stains, cells were incubated 
in the dark at –4 ° C for 30 min with mAbs at concentrations rec-
ommended by the manufacturer, washed twice with phosphate-
buffered saline, blocked with 1% bovine serum albumin and 
thereafter fixed in phosphate-buffered saline with 1% formalde-
hyde and 0.01% NaN 3 and stored at –4 ° C in the dark until analy-
sis. For intracellular staining with anti-FoxP3, cells were stained 
against the superficial markers CD4 and CD25 as above. After 1 
wash, cells were permeabilized, washed, blocked and stained us-
ing the buffers and instructions provided by the manufacturer 
(eBioscience) and thereafter fixed and stored as above. Flow cyto-
metric analysis was performed within 24 h. The flow cytometry 
data were analyzed using CellQuest software (BD Bioscience). 
 Cell Proliferation Assay  
 PBMCs were obtained from patients and controls as described 
above. CD4+CD25hi+ (T reg ) and CD4+CD25hi– (responders) T 
cells were separated from PBMCs using magnetic separation by 
RoboSep (StemCell, Vancouver, Canada). Cell purity was assessed 
by flow cytometry using fluorescently labeled anti-CD4-perCP 
and anti-CD25-APC mAbs. Before seeding, U-bottom 96-well 
plates were coated with anti-CD3 (0.5   g/ml for 4–16 h at –4 ° C). 
To measure cell proliferation, 1  ! 10 4 CD4+CD25hi– T cells/well 
were seeded, and then increasing numbers (1: 0, 1: 8, 1: 4, 1: 2) of 
CD4+CD25hi+ (T reg ) cells were added and cocultured for 48 h. 
Cells were cultured in a final volume of 200   l PBMC cell culture 
medium consisting of RPMI 1640 with glutamine containing 10% 
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human AB serum, 1% HEPES 1  M , 1% penicillin-streptomycin-
glutamine (Cambrex, Ariz., USA) and 1% Na pyruvate 100  M at 
37 ° C in 5% CO 2 for 48 h. Thereafter, cell plates were centrifuged 
at 1,400 rpm for 8 min. Cell proliferation was measured using
CyQuant proliferation kit (Invitrogen, Molecular Probes, N.Y., 
USA).
 Data Presentation and Statistics 
 Baseline characteristics and lymphocyte counts are presented 
as means  8 standard deviation. SPSS version 11.5 and GraphPad 
Prism version 4.0 software packages were used for statistical anal-
ysis and graph editing. Mann-Whitney U, Student’s t and Wil-
coxon tests were used for comparative analysis between groups as 
appropriate. A p value  ! 0.05 was considered statistically signifi-
cant. 
 Results 
 Patient Characteristics  
 We enrolled 36 patients (26 females) and 33 healthy 
controls (15 females) at a mean age of 51  8 11 and 43  8 
9 years (p = 0.05) in the study upon informed consent. 
Pulmonary hemodynamic characteristics of the pa-
tients were: mean pulmonary arterial pressure 49  8 14 
mm Hg, cardiac index 2.3  8 0.7 l  min –1  m –2 , pulmo-
nary vascular resistance 858  8 364 dyn  s  m –5 , pulmo-
nary capillary occlusion pressure 8.9  8 4.1 mm Hg, 
right arterial pressure 8.1  8 5.4 mm Hg, arterial oxygen 
saturation 93  8 6%, and mixed venous oxygen satura-
tion 54  8 9%. The mean time between the diagnostic 
right heart catheter date and the blood analysis was 10 
 8 10 months. Twenty-five patients (68%) were treated 
with continuous intravenous epoprostenol, 3 of which 
had a combination therapy with oral bosentan. Two pa-
tients (5%) were treated with inhaled iloprost and 1 pa-
tient with sildenafil. Eight patients (22%) did not receive 
a specific therapy for PAH.
 Differential Frequencies of Lymphocyte Subclasses 
and T reg Cells 
 Within the T cell subset, we found a tendency toward 
an increase in the percentage of CD4+ T cells in the pe-
ripheral blood of IPAH versus controls (83  8 1.7 vs. 78 
 8 2.7%; p = 0.11) at the expense of a significant decrease 
in CD8+ T cells (11  8 1.2 vs. 18  8 2.5%; p = 0.02) ( fig. 1 ). 
The CD4/CD8 relation consecutively decreased (p = 
0.007) ( fig.1 ). Within the CD4+ T cell compartment, we 
found significantly more CD25hi+ T cells in patients 
compared with controls (5.9  8 0.8 vs. 3.5  8 0.3%; p = 
0.009) and a significantly increased number of FoxP3+ 
T reg cells (10.1  8 1.5 vs. 4.5  8 0.35% of all CD4+ T cells; 
p  ! 0.001) ( fig. 2 ,  3 ). However, the percentage of FoxP3+ 
cells within the CD25hi+CD4+ T reg cells in each group 
was similar (61.6  8 2.8 vs. 62.0  8 4.0%; p = 0.93). We 
found no difference in the lymphocyte subsets between 
patients who received PAH-specific therapy and therapy-
naïve patients. We neither found a difference in the lym-
phocyte subsets between patients with a time span be-
tween the diagnostic pulmonary artery catheter of more 
and less than 10 months.
 Proliferation Assay  
 The proliferation assay of T lymphocytes from the 
blood of IPAH patients (n = 16) and healthy controls (n = 
13) was performed in triplicate. Test performance was 
monitored by a respective linear rise of relative light units 
with increasing standard number of cells/well. Patient 
1.0
n.s.
CD4+/CD3+
0.8
0.6
0.4
0.2
Healthy IPAH
0
CD8+/CD3+
1.0
p = 0.02
0.8
0.6
0.4
0.2
Healthy IPAH
0
CD4+/CD8+
100
%
p = 0.007
80
60
40
20
Healthy IPAH
0
 Fig. 1. Differential frequencies of CD4+ 
and CD8+ T lymphocyte (CD3+) subsets 
for IPAH patients and controls. n.s. = Not 
significant.  
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
7/
7/
20
16
 1
1:
57
:3
2 
AM
 Lymphocyte Subsets in IPAH Respiration 2008;75:272–280 275
CD4+CD25– T cells (responder cells) were found to have 
proliferated slightly more than cells from healthy con-
trols (9,731  8 2,638 vs. 7,715  8 1,310 relative light units); 
however, the difference was not statistically signifi-
cant (p = 0.6). Addition of increasing numbers of 
CD4+CD25+ T cells equally suppressed the anti-CD3-
induced proliferation of CD4+CD25– T cells in patients 
or controls (data not shown). 
 Discussion 
 In the present study, we found an increased percentage 
of CD25high+ and FoxP3+CD4+ T reg cells and a de-
creased percentage of CD8+ T cells in the peripheral 
blood of patients with IPAH compared with healthy con-
trols. The percentage of FoxP3+ T cells within the 
CD25+CD4+ T cell subset of IPAH and controls was 
comparable, which still signifies a higher total percentage 
of FoxP3+CD25+ T reg cells in IPAH due to their higher 
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CD4-PerCPd
11.004
104103102101100
104
103
102
101
100
C
D
25
-A
PC
Healthy
CD4-PerCPe
11.003
104103102101100
104
103
102
101
100
C
D
25
-A
PC
CD25-APC
11.004
104103102101100
104
103
102
101
100
Fo
xP
3-
PE
CD4-PerCP
11.004
104103102101100
104
103
102
101
100
Fo
xP
3-
PE
IPAH
1,000
800
600
400
200
0
0 200 400
SSC-Heighta
11.004
600 800 1,000
FS
C
-H
ei
g
h
t
200
0
CD25-APCb c
104103102101100
C
ou
n
ts
IPAH
200
0
FoxP3-PE
104103102101100
C
ou
n
ts
CD25-APC
11.003
104103102101100
104
103
102
101
100
Fo
xP
3-
PE
CD4-PerCP
11.003
104103102101100
104
103
102
101
100
Fo
xP
3-
PE
 Fig. 2. Representative samples of flow cytometric findings are 
shown for a patient with IPAH and a healthy control.  a A typical 
forward side scatter with the gated lymphocytes encircled in 
black.  b ,  c Typical histograms of CD25+ ( b ) and FoxP3+ ( c ) T cells 
from IPAH patients, indicating also the typical histogram in 
healthy controls (Ctrl).  d ,  e Four field charts show typical cell dis-
tributions for the markers of interest (CD4, CD25 and FoxP3) for 
IPAH patients ( d ) and healthy controls ( e ).  
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percentage of CD25+ T cells ( fig. 3 ). Our findings of a dif-
ferential prevalence of some of the T cell subsets between 
IPAH and controls may point toward a pathogenetic role 
of the T cell compartment in PAH, as has recently been 
demonstrated in an animal model  [27] . However, we are 
aware that the interpretation of our findings in the pe-
ripheral blood of IPAH compared with controls is diffi-
cult and does not allow to draw firm conclusions about 
pathogenetic pathways, causes and consequences in the 
pulmonary vasculature. Nevertheless, we present some 
speculations below in the hope to inspire future research 
in the field. 
 The transcription factor FoxP3, which is expressed by 
the majority of CD25+CD4+ and also by a fraction of 
CD25–CD4+ T cells, is the most reliable and specific 
marker of naturally occurring T reg cells  [35, 37] . The over-
all increase in FoxP3+CD4+ T cells in the blood of IPAH 
with an unchanged percentage of FoxP3+ cells within the 
CD25+CD4+ T cell subset indicates that at least some of 
the increased number of the FoxP3+ T cells can be attrib-
uted to a peripheral conversion of CD25–CD4+ T cells 
into T reg cells  [53] . Conversion of CD4+ T cells in the pe-
riphery into T reg cells by de novo FoxP3+ expression has 
been described in various diseases in order to control an 
exaggerated immune response  [36, 37, 53, 54] . Recent re-
ports underscore that T reg cells not only play a central role 
in the maintenance of immunotolerance  [30, 36–38, 54] , 
but that they are also potent inhibitors of antitumor and 
possibly antiviral immune responses  [25, 42–45] . Mono-
clonal cancer-like endothelial proliferation is a key histo-
pathological finding in IPAH  [1, 3, 23, 55] . 
Therefore, we speculate that the increase in T reg cells in 
the peripheral blood of IPAH could be attributed to the 
necessity to suppress any self-reactive T cells (possibly to-
wards the cancer-like endothelial proliferation) in anal-
ogy to the postulated function of increased T reg cells in 
cancer  [56, 57] . Tumor immune surveillance by T reg cells 
is apparently insufficient to suppress the emergence of 
cancer. A possible clue to this issue is the finding that 
many tumor antigens are recognized by autologous cyto-
toxic T cells  directed against normal self-constituents 
 [57] , thus indicating that tumor immunity is to some de-
gree also autoimmunity. Whether cytotoxic T cells direct-
ed towards self-constituents might be involved in the 
pathogenesis of PAH is not known to date, but several 
findings already point toward a role of autoimmunity in 
PAH  [8] . Our findings of increased T reg cells in IPAH sup-
port this hypothesis. A functional hallmark of naturally 
occurring T reg cells is that they suppress the activation and 
expansion of self-reactive T cells and inhibit the develop-
ment of autoimmune disease  [37] . The high sensitivity of 
T reg cells toward self- and non-self antigens and their high 
activity of bystander suppression of other T cells suits 
their role of sustaining self-tolerance, but potentially hin-
ders tumor immunity or the proper work of the acquired 
immune system in viral defense. Another speculation is 
that the peripheral conversion of CD4+ T cells into T reg 
cells could be induced by microbial, particularly viral, in-
fection. The association of some chronic viral infections 
with pulmonary hypertension is well known  [52, 58, 59] , 
and some findings point toward a potential role of micro-
bial (mainly viral) antigen mimicry in the pathogenesis of 
IPAH  [60] , although to date, no specific microbial antigen 
could be consistently demonstrated  [61, 62] . Besides an 
increase in T reg cells, in the present study, we also found a 
significant decrease in CD8+ T cells. A decreased number 
or impaired function of CD8+ T cells (so called exhausted 
T cells) has been described in chronic viral infections  [63–
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0
Proportion of CD25+
within CD4+ T cells
p = 0.009
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within CD4+CD25+
 Fig. 3. Differential frequencies of lympho-
cyte subclasses for IPAH patients and con-
trols for CD25+ and FoxP3+CD4+ and 
FoxP3+CD25+CD4+ T cells. p values in-
dicate the level of significance of the dif-
ference (2-sided t test). 
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66] . It is conceivable that a yet unknown factor in chronic 
viral infections of the pulmonary vasculature in PAH 
would trigger a depletion of cytotoxic T cells along with 
an increase in T reg cells. Moreover, such a viral infection 
might also provoke the expression of epitopes on immune 
or endothelial cells against which an altered immune re-
sponse in PAH might be directed. Future studies with a 
focus on the detection of viral or self antigens in the pul-
monary vasculature against which the altered T cell sub-
sets are directed would be desirable. 
 Plexiform lesions in lung tissue of patients with pulmo-
nary hypertension are not only surrounded by lympho-
cytes and mast cells  [21, 67] , but also by dendritic cells 
(DCs), as has been described recently  [68] . DCs play a role 
in immune regulation as professional antigen-presenting 
cells and controllers of the differentiation of naïve T cells 
into T reg cells  [69, 70] . Whereas inflammatory stimuli in-
duce DC maturation, which direct naïve T cells to differ-
entiate into effector T cells, immature DCs were only re-
cently acknowledged to have an important role in the 
maintenance of immune tolerance through induction of 
T reg cells  [69, 71, 72] . On the other hand, T reg cells talk back 
to DCs restraining their maturation and antigen presenta-
tion  [73] . Therefore, it could be hypothesized that our find-
ing and the finding of Perros et al.  [68] point towards a 
mutual interaction between T reg cells and DCs in order to 
keep up a state of tolerance. It remains to be questioned at 
which time point in the course of the disease such a state 
of tolerance develops, e.g., it could be imagined that an au-
toimmune constellation early in the disease course would 
later on develop into a state of tolerance with increased T reg 
cells and DCs. However, in our study population, we found 
no difference between lymphocyte subsets obtained from 
patients within 10 months of the initial right heart cathe-
terization and lymphocyte subsets obtained from patients 
with a time span of more than 10 month from diagnosis, 
although our study was not designed to look at changes of 
lymphocyte subsets over time. 
 The association of PAH with various autoimmune dis-
orders is well known  [8, 9, 24, 74–78] , and findings such 
as anti-endothelial cell or anti-fibroblast antibodies in 
patients with IPAH or scleroderma-associated PAH sug-
gest a pathogenetic role of autoimmunity in PAH  [19, 20] . 
As many autoimmune diseases have been found to be as-
sociated with decreased T reg cells  [36, 40, 46, 49, 79] , our 
findings of increased T reg cells might be unexpected. Pos-
sible explanations could be that T reg cells in the periph-
eral blood would be reactively elevated, along with a pos-
sible decrease in T reg cells early in the disease course, or 
that, as discussed above, the increased T reg cells represent 
some state of immune tolerance in the course of the dis-
ease, possibly induced by a tumor or infectious antigen, 
leading to cancer-like proliferations in the pulmonary 
vasculature  [46, 55] .
 Another possibility would be that the difference in 
lymphocyte subsets between our patients and controls 
could be attributed to simple confounders like age, gender 
or drug use. Patients were on average slightly older and 
more likely to be female than controls. In normal humans, 
total lymphocyte count, CD8+ T and CD19+ B cell subsets 
have been described to decrease beyond the age of 50 
years, whereas female sex is related to higher CD4+ T cells 
 [80] , data on T reg cells is lacking. As our patients were on 
average slightly older than 50 years (51  8 11), it cannot be 
excluded that some of the differences we found between 
patients and controls could be attributed to age. 
 Drug use might alter T reg cell number and possibly ac-
tivity as well. Steroids have been found to increase T reg 
cells  [81, 82] ; therefore, we included only steroid-naïve pa-
tients. Nevertheless, specific drugs used in the treatment 
of PAH (such as prostanoids, endothelin receptor antago-
nists or phosphodieasterase inhibitors) have a potential to 
influence immune regulation and thereby  lymphocyte 
subsets  [83–86] . Sixty-eight percent of the patients in our 
cohort were on continuous intravenous epoprostenol 
therapy. All the same, we did not find a difference in lym-
phocyte subsets between treated and untreated patients. 
However, this study was not designed to look for effects of 
therapy on lymphocyte subsets; therefore, it could still be 
possible that some of the observed differences between 
patients and controls can be attributed to therapy. Future 
studies are warranted to answer questions about the influ-
ence of therapy on lymphocyte subsets.
 In summary, we believe that our findings of increased 
T reg cells and decreased CD8+ T cells in the peripheral 
blood of patients with IPAH are important and may have 
significant implications in directing future research in the 
field. Whether alterations in lymphocyte subsets actually 
play a role in the pathobiology of PAH and whether they 
are a cause or a consequence remains to be investigated.
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